PUBLISHER: The Business Research Company | PRODUCT CODE: 1760528
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760528
Electrocompetent cells are bacterial cells specially prepared to enhance their capacity to absorb foreign deoxyribonucleic acid (DNA) through electroporation. Their membranes become permeable through a washing procedure using a cold, ion-free solution, typically containing glycerol or water. Upon exposure to a brief electric pulse, membrane pores open, permitting plasmid DNA to enter. These cells are widely used when high transformation efficiency is crucial in genetic engineering.
The primary product categories of electrocompetent cells include bacterial electrocompetent cells, yeast electrocompetent cells, plant electrocompetent cells, and mammalian electrocompetent cells. Bacterial electrocompetent cells are designed with permeable membranes to facilitate efficient DNA uptake during electroporation. These cells use various technologies such as electroporation, chemical transformation, and others, and are offered in multiple packaging formats including tubes, plates, and customized options. Their applications span gene cloning, protein expression, transfection studies, gene editing, therapeutic research, and more. They are utilized by a range of end users, including pharmaceutical and biotechnology firms, academic and research institutions, contract research organizations (CROs), and others.
The electrocompetent cells market research report is one of a series of new reports from The Business Research Company that provides electrocompetent cells market statistics, including the electrocompetent cells industry global market size, regional shares, competitors with the electrocompetent cells market share, detailed electrocompetent cells market segments, market trends, opportunities, and any further data you may need to thrive in the electrocompetent cells industry. This electrocompetent cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The electrocompetent cells market size has grown rapidly in recent years. It will grow from $1.43 billion in 2024 to $1.58 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth observed during the historic period can be attributed to the increasing demand for recombinant protein production, a rise in academic and government research funding, the expansion of molecular biology research, the adoption of gene cloning methods, and the availability of high-efficiency E. coli strains.
The electrocompetent cells market size is expected to see rapid growth in the next few years. It will grow to $2.31 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The projected growth in the forecast period is driven by expanding applications in synthetic biology, rising demand for CRISPR-based gene editing, the growth of personalized medicine research, the emergence of automation in transformation procedures, and increased investments from biotech startups. Key trends anticipated during this period include CRISPR-compatible electrocompetent cells, high-efficiency transformation strains, integration of chemically defined growth media, automated cell preparation processes, and cold-chain optimized packaging to ensure product stability.
The growing demand for genetic engineering is expected to drive the expansion of the electrocompetent cells market. Genetic engineering involves the deliberate alteration of an organism's DNA to change its characteristics or functions. This demand is largely fueled by the need to boost agricultural productivity through the development of high-yield, pest-resistant crops, which reduce dependence on chemical inputs. As genetic engineering becomes more integral across agriculture, healthcare, and research, the need for high-quality electrocompetent cells-used to efficiently introduce foreign DNA into cells-is also increasing. For example, in April 2025, the Economic Research Service, a U.S. government agency, reported that in 2024, genetically engineered insect-resistant seeds were planted on 90% of cotton acreage in the U.S. As such, the rising use of genetic engineering is contributing to the growth of the electrocompetent cells market.
Leading companies in the electrocompetent cells market are focusing on innovations such as automated cell processing technologies to support the scalability of genetic engineering applications. These automated systems manage tasks such as cell handling, cultivation, modification, and preservation using software-driven protocols, which enhance efficiency, consistency, and scalability-especially in fields such as cell therapy, regenerative medicine, and biomanufacturing. For instance, in March 2022, Thermo Fisher Scientific Inc., a U.S.-based biotechnology firm, introduced the Gibco CTS Xenon electroporation system. This large-volume, customizable electroporation platform is designed for rapid, non-viral gene modification and enables seamless transition from clinical to commercial-scale production. It offers programmable conditions, maintains high cell viability (up to 80%), and delivers efficient gene knockout (up to 90%) for hard-to-transfect cells within a sterile, closed system.
In January 2024, MaxCyte Inc., a U.S.-based provider of electroporation systems, formed a partnership with Wugen Inc. to enhance scalable cell engineering technologies for cancer treatment. The collaboration aims to accelerate the clinical and commercial manufacturing of Wugen's allogeneic, off-the-shelf cell therapies, which are designed to treat both hematologic and solid tumor cancers. By leveraging MaxCyte's efficient, scalable cell engineering technology, the partnership seeks to advance therapeutic options for patients with limited treatments available. Wugen Inc. is a U.S.-based company specializing in cellular therapies for cancer.
Major players in the electrocompetent cells market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Lonza Biosciences, Bio-Rad Laboratories Inc., Takara Bio Inc., Promega Corporation, New England Biolabs, OriGene Technologies, MaxCyte, LGC Biosearch Technologies, IBA GmbH, Zymo Research, Creative Biolabs, Inovio Pharmaceuticals Inc., Canvax, Yeastern Biotech, ZellBio GmbH, Scarab Genomics LLC, and Intact Genomics.
North America was the largest region in the electrocompetent cells market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in electrocompetent cells report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the electrocompetent cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The electrocompetent cells market consists of revenues earned by entities by providing services such as custom strain development, plasmid DNA amplification, library construction, and technical support for molecular biology applications. The market value includes the value of related goods sold by the service provider or included within the service offering. The electrocompetent cells market includes sales of insect electrocompetent cells, fungal electrocompetent cells, and algal electrocompetent cells. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Electrocompetent Cells Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on electrocompetent cells market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for electrocompetent cells ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The electrocompetent cells market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.